Background/Aims: The effects of multiple-dose bupropion on the pharmacokinetics of single-dose carvedilol were investigated in order to evaluate this possible drug-drug interaction. Methods: A preclinical study was conducted among white male Wistar rats. Each rat was cannulated on the femoral vein prior to being connected to BASi Culex ABC®. During the reference period, each rat received an intravenous and an oral dose of 3.57 mg/kg body weight (b.w.) carvedilol, at 2 days distance. After 5 days of pretreatment with 21.42 mg/kg b.w. bupropion (by oral route, twice a day - given in order to reach the steady state), during the sixth day, 3.57 mg/kg b.w. carvedilol and 21.42 mg/kg b.w. bupropion were orally co-administrated (test period). After each administration of carvedilol, several samples of 200 µL blood were collected. The pharmacokinetic parameters of carvedilol were analyzed by the noncompartmental method. Results: The 5 days pretreatment with bupropion increased the exposure to carvedilol in rats by 180%, considering the modifications observed in the area under the curve of carvedilol. Carvedilol was shown to have higher plasma concentrations, delay in maximum concentration, and a prolonged half-life, after being pretreated with bupropion. Conclusion: The administration of multiple-dose bupropion influences the pharmacokinetics of carvedilol (single oral dose) in rats.

1.
Cullington D, Yassin A, Cleland J: Beta-blockers in the treatment of cardiovascular disease. Prescriber 2008;19:31-39.
2.
Lainscak M, Moullet C, Schön N, Tendera M: Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. Int J Cardiol 2007;122:149-155.
3.
Morgan T: Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994;26:335-346.
4.
Phuong NT, Lee BJ, Choi JK, Kang JS, Kwon KI: Enantioselective pharmacokinetics of carvedilol in human volunteers. Arch Pharm Res 2004;27:973-977.
5.
Oldham HG, Clarke SE: In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos 1997;25:970-977.
6.
Ishida K, Taira S, Morishita H, Kayano Y, Taguchi M, Hashimoto Y: Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. Biol Pharm Bull 2008;31:1297-1300.
7.
Jefferson JW, Pradko JF, Muir KT: Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 2005;27:1685-1695.
8.
Maneeton N, Maneeton B, Intaprasert S, Woottiluk P: A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 2014;10:1439-1449.
9.
Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ: CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000;28:1176-1183.
10.
Reese MJ, Wurm RM, Muir KT, Generaux GT, St John-Williams L, McConn DJ: An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 2008;36:1198-1201.
11.
Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, Adson DE: Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 2005;25:226-229.
12.
Schmid Y, Rickli A, Schaffner A, Duthaler U, Grouzmann E, Hysek CM, Liechti ME: Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. J Pharmacol Exp Ther 2015;353:102-111.
13.
Paslakis G, Gilles M, Deuschle M: Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series. J Clin Psychopharmacol 2010;30:473-474.
14.
McCollum DL, Greene JL, McGuire DK: Severe sinus bradycardia after initiation of bupropion therapy: a probable drug-drug interaction with metoprolol. Cardiovasc Drugs Ther 2004;18:329-330.
15.
Butnariu A, Popa DS, Vlase L, Andreica M, Muntean D, Leucuța S: New high-throughput liquid chromatographic tandem mass spectrometry assay for therapeutic drug monitoring of carvedilol in children with congestive heart failure. Rev Romana Med Lab 2009;15:7-15.
16.
Lewis DF, Sheridan G: Cytochromes P450, oxygen, and evolution. ScientificWorldJournal 2001;1:151-167.
17.
Lynch T, Price A: The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007;76:391-396.
18.
Katon WJ: Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003;54:216-226.
19.
Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D: Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 2006;23:1675-1686.
20.
Wang L, Wang S, Chen M, Chen X, Lin Y, Hu X, Huang X, Li X, Hu G: Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats. Drug Dev Ind Pharm 2015;41:1661-1666.
21.
Lim TH, Cho YA, Choi DH: Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats. J Physiol Pharmacol 2015;66:591-597.
22.
Lee CK, Choi JS: Effects of glipizide on the pharmacokinetics of carvedilol after oral and intravenous administration in rats. Biomol Ther 2011;19:237-242.
23.
Choi JS, Choi DH: Pharmacokinetic drug interaction between carvedilol and ticlopidine in rats. Biomol Ther 2010;18:343-349.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.